Manila Bulletin
Astrazeneca withdraws application to conduct COVID-19 vaccine clinical trials in PH
British pharmaceutical firm AstraZeneca has withdrawn its application for Phase 3 clinical trials of its COVID-19 vaccine in the Philippines.
AstraZeneca indicated that it already had sufficient data to see the efficacy of its vaccine.
However, AstraZeneca may still supply vaccines in the Philippines once it gets a green light from the FDA.
AstraZeneca-Oxford's COVID-19 vaccine has been found 70% effective against COVID-19 at first half dose, but it increases to 90% after the second full dose is administered.
The vaccine's price range is cheaper at $3 to $4 compared with American firms Moderna and Pfizer-BioNTech, whose vaccines cost more due to the requirement of ultra-low freezer storage.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
Pharmaceutical companies may start clinical trials for COVID-19 vaccines in the Philippines this month, according to Department of Science and Technology Secretary Fortunato de la Pena.
Read more →
The Philippines is in talks with China for its first COVID-19 vaccine, with an expected administration in March 2021.
Read more →
Two American biotech firms, Moderna and Arcturus, are willing to supply the Philippines between four to 25 million doses of their COVID-19 vaccines.
+1
Read more →
The Philippines' vaccination czar, Secretary Carlito Galvez Jr., stated that a Chinese COVID-19 vaccine might be the first to arrive in the country.
Read more →